News

Dr Mehta has extensive biotechnology and financial industry experience, and since 2006 has been managing director of Gemini Strategies, a manager of small-cap institutional funds with investments in

According to the company, the study results showed a reduced macrophage content in the fat tissue of Lisofylline (LSF)-treated mice, when compared to controls, indicating its immune modulating

The principal investigators for the study are Dean Tang, associate professor of division of carcinogenesis and adjunct associate professor of college of pharmacy at The University of Texas

Sequenom has previously announced that it would terminate the exchange offer if Exact Sciences entered into any out-licensing agreement, collaboration or financial restructuring. Sequenom continues to be committed

Taro has received tentative approval for this abbreviated new drug application (ANDA) in March 2008. Lamotrigine is a prescription product used for the treatment of seizures and is

The company has also delivered the GMP grade product to Neogenix in preparation for Phase I/II clinical trials planned for the first half of 2009. NPC-1C is a

The study has demonstrated that repeat intravenous treatment with pegylated-rHuPH20 enzyme (PEGPH20) as a single agent in the PC3 mouse model resulted in approximately 70% (p=0.001) tumor growth

The reduction in workforce will extend the company’s existing cash resources to fund operations until around the end of 2009. The measures are expected to be implemented with

In Australia, Meridian has signed an agreement with Sydney-based Immuno. For Argentina, Meridian has signed with Scott Pharma, a healthcare distributor. This decision is consistent with Meridian’s stated